CTLA4 and cancer: Among these are monoclonal antibodies that target cancer immune checkpoint inhibitors (ICIs) including anti-CTLA-4, anti-PD-1, and anti-PD-L1/2 antibodies that are able to restore anticancer immunity and are widely used for the management of various cancers, including melanoma17.